Please login to the form below

trial failure

This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.

Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Bispecific antibody fails in non-small cell lung cancer trial. Bintrafusp alfa – the novel immunotherapy at the centre of a major alliance between GlaxoSmithKline (GSK) and Merck KGaA – has failed in ... Although GSK has not issued a press release

Latest news

Galapagos mid-stage trial failure raises concerns for Gilead deal

While we are disappointed that ADAMTS-5 inhibition by GLPG1972 proved not to make a difference in this trial, we want to express our gratitude to all participating patients and investigators,” ... Gilead can pin some of its hopes on another of
FDA sets November date for expert panel review of Biogen’s aducanumab

Biogen maintained that the failure of aducanumab in a second trial – ENGAGE – was most likely due to the fact that there weren’t a sufficient number of patients receiving enough exposure
Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Biogen maintained that failure in the second trial of aducanumab was likely due to the fact that there weren’t a sufficient number of patients receiving enough exposure to the higher
Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial

The EMPEROR-Reduced trial evaluated SGLT2 inhibitor Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF). ... Aside from the EMPEROR-Reduced trial, Boehringer/Lilly is also investigating Jardiance as a treatment
Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations. Bayer and Merck &Co have unveiled the data from their phase 3 trial of vericiguat in high-risk heart failure, backing up a ... The patients in the trial were well treated, with more than a

More from news
Approximately 26 fully matching, plus 76 partially matching documents found.

Latest Intelligence

Transforming clinical trial data into a long-term asset

Moreover, published literature tends to catalogue successful clinical trials, but data from an unsuccessful trial – provided its failure did not result from safety issues – can still help make the case for ... Yet it seems that numerous archives of
COVID-19: the race to find a vaccine

A subsequent leak about the apparent failure of remdesivir in a Chinese trial then dampened expectations again. ... A clinical trial of Regeneron’s drug is scheduled to start in June.
For trials without tribulations, we must improve patient experience

The result of this consultation is Havas Lynx Group’s latest white paper‘Patient Centricity on Trial’. ... This kind of simple, practical question can be the difference between success and failure of a clinical trial, and is usually only raised by
VIDEO interview: Neil Weir, UCB

Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. ... Particularly when we have high failure rates in late stages in clinical studies,
Customer valuation in pharma

Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

Alzheimer's: the numbers we cannot forget

This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose
A forward march for adaptive designs

For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Senior Content Editor - Biotechnology: Salary TBC

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Principal Medical Writer: Varies on experience

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

PMHub

Add my company

Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...